FBT is the “laggard” among biotech ETFs with a 38.7% year-to-date gain. Investors were not shy about pouring cash into biotech funds in July, either. Combined, BBH, FBT and IBB took in over $486 million in new assets, according to Index Universe data. Surprisingly, XBI saw outflows of $22 million.
SPDR S&P Biotech ETF
ETF Trends editorial team contributed to this post.